Earnings Summary

Lyell Immunopharma, Inc’s revenue fell -73.13% since last year same period to $0.01Mn in the Q4 2023. On a quarterly growth basis, Lyell Immunopharma, Inc has generated -48% fall in its revenue since last 3-months.

Lyell Immunopharma, Inc’s net profit fell -2270.5% since last year same period to $-52.93Mn in the Q4 2023. On a quarterly growth basis, Lyell Immunopharma, Inc has generated -4.08% fall in its net profits since last 3-months.

Lyell Immunopharma, Inc’s net profit margin fell -8178.62% since last year same period to -407153.85% in the Q4 2023. On a quarterly growth basis, Lyell Immunopharma, Inc has generated -100.16% fall in its net profit margins since last 3-months.

Lyell Immunopharma, Inc’s earning per share (EPS) estimates for the current quarter stand at -0.21 - a 8.7% jump from last quarter’s estimates.

Lyell Immunopharma, Inc’s earning per share (EPS) estimates for the current year stand at -0.21.

Lyell Immunopharma, Inc’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2024. This indicates that the Lyell Immunopharma, Inc has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.